Yuh‐Shan Jou

Institute of Biomedical Sciences, Academia Sinica — Taiwan

Biochemistry, Genetics and Molecular Biology · Life Sciences

40h-index4.9kcitations98works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(19), Genetic Associations and Epidemiology(9), Cancer-related Molecular Pathways(8), Cancer, Hypoxia, and Metabolism(8), Histone Deacetylase Inhibitors Research(8)

Publications98 total

Protocol to quantify site-specific carbohydrate sulfation at immune checkpoint proteins in mammalian cells
STAR Protocols·2025Open Access
PSPC1 bridges cancer stemness and malignancy in acute myeloid leukemia
Cell stem cell·2025
Correction: A novel HIF1α-STIL-FOXM1 axis regulates tumor metastasis
Journal of Biomedical Science·2024Open Access
Abstract 6215: Systematic identification and clinical implications of glycogenes in cancer research: An integrative omics approach
Cancer Research·2024
Four-dimensional omics data reveals ribosome heterogeneity, regulation of translation efficacy, and nonsense-mediated decay in the differentiation of spermatocyte to round spermatid
2023· 1 citedOpen Access
Data from HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
2023Open Access
Supplementary Methods, Tables 1 - 3, Figures 1 - 7 from HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
2023Open Access
Data from HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
2023Open Access
Supplementary Methods, Tables 1 - 3, Figures 1 - 7 from HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
2023Open Access
Somatic A‐to‐I RNA‐edited RHOA isoform 2 specific‐R176G mutation promotes tumor progression in lung adenocarcinoma
Molecular Carcinogenesis·2022· 9 citedOpen Access
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression
Journal of Hematology & Oncology·2022· 21 citedOpen Access
A novel HIF1α-STIL-FOXM1 axis regulates tumor metastasis
Journal of Biomedical Science·2022· 23 citedOpen Access
Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma
Computational and Structural Biotechnology Journal·2022· 7 citedOpen Access
PSPC1 is a new contextual determinant of aberrant subcellular translocation of oncogenes in tumor progression
Journal of Biomedical Science·2021· 8 citedOpen Access
PSPC1 Potentiates IGF1R Expression to Augment Cell Adhesion and Motility
Cells·2020· 18 citedOpen Access
PSPC1: a contextual determinant of tumor progression
Molecular & Cellular Oncology·2020· 10 citedOpen Access
PSPC1-interchanged interactions with PTK6 and β-catenin synergize oncogenic subcellular translocations and tumor progression
Nature Communications·2019· 40 citedOpen Access
Integrative analyses of noncoding RNAs reveal the potential mechanisms augmenting tumor malignancy in lung adenocarcinoma
Nucleic Acids Research·2019· 39 citedOpen Access
A New Switch for TGFβ in Cancer
Cancer Research·2019· 111 citedOpen Access
Abstract 2137: Aberrant nuclear-expressed SLC29A2 as a therapeutic target in hepatocellular carcinoma
Experimental and Molecular Therapeutics·2019
page 1 of 5Next →

Frequent Co-authors

Cathy S.J. Fann(8), Chian‐Feng Chen(7), Chin‐Fu Hsiao(7), Pan‐Chyr Yang(6), Ruey‐Hwa Chen(5), Wei J. Chen(5), Yaw‐Dong Lang(4), De-Leung Gu(4), Ding‐Shinn Chen(4), Pei‐Jer Chen(4), Kuen‐Tyng Lin(4), Y. M. Dennis Lo(4), Gee‐Chen Chang(4), Wu‐Chou Su(4), Yuh‐Min Chen(4), Ming‐Shyan Huang(4), Chao A. Hsiung(4), Chih‐Min Liu(4), Wen‐Hung Chung(4), Tzung‐Jeng Hwang(4)